USA – Pfizer Inc. and Valneva SE, have announced additional positive Phase 2 data for their Lyme disease vaccine candidate, VLA15, the only Lyme disease vaccine candidate currently in clinical…
Read MoreTag: Lyme disease
Valneva, Pfizer set to rollout phase 2 trials of its Lyme disease vaccine candidate
WORLD – Valneva, a specialty vaccine company for infectious diseases, and Pfizer, have completed their recruitment for the phase 2 trials, VLA15-221, of Lyme disease vaccine candidate, VLA15. The trial…
Read More